 Home > Biochemistry News > Biotechnology News > 88% objective response rate bispecific antibody preliminary clinical results released

88% objective response rate bispecific antibody preliminary clinical results released

 Last Update: 2021-09-19
 Source: Internet
 Author: User

Tags

open end manometer

2 3 dpg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Genmab and AbbVie announced that the results of the phase 1/2 clinical trial EPCORE NHL-1 of the CD3/D20 bispecific antibody epcoritamab, which is under development, were published in the well-known academic journal "The Lancet"
.

The trial evaluated the safety and efficacy of the therapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL)

A bispecific antibody is an antibody molecule that can specifically bind to two different antigens
.

Epcoritamab is a bispecific T cell redirection antibody

The dose-escalation part of the open-label, multicenter EPCORE NHL-1 trial was carried out in 68 patients with relapsed/refractory CD20-positive B-cell non-Hodgkin’s lymphoma (B-NHL), including diffuse large B-cell lymphoma Tumors and follicular lymphoma
.

The test results showed that no dose-limiting toxicity was observed during the dose escalation process, and the recommended dose (RP2D) for the phase 2 clinical trial was determined to be 48 mg
.

Common adverse events (AE) in patients with relapsed/refractory DLCBL were fever (69%), mainly related to cytokine release syndrome (CRS) (59%, all grades 1-2) and injection site reactions (47%) , All are level 1) related

In patients with relapsed/refractory DLCBL who received RP2D therapy (n=8), the preliminary efficacy results reported in the trial showed that the patients achieved an overall response rate (ORR) of 88% and a complete response (CR) of 38%
.

Secondly, patients (n=22) who received 12-60 mg epcoritamab achieved 68% ORR and 45% CR

Reference materials:

[1] Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.